Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Tumor-infiltrating lymphocytes are dynamically desensitized to antigen but are maintained by homeostatic cytokine
Bijan Boldajipour, Amanda Nelson, Matthew F. Krummel
Bijan Boldajipour, Amanda Nelson, Matthew F. Krummel
View: Text | PDF
Research Article Immunology Oncology

Tumor-infiltrating lymphocytes are dynamically desensitized to antigen but are maintained by homeostatic cytokine

  • Text
  • PDF
Abstract

T cells that enter tumors are largely tolerized, but how that process is choreographed and how the ensuing “dysfunctional” tumor-infiltrating lymphocytes (TILs) are maintained are poorly understood and are difficult to assess in spontaneous disease. We exploited an autochthonous model of breast cancer for high-resolution imaging of the early and later stages of tumor residence to understand the relationships between cellular behaviors and cellular phenotypes. “Dysfunctional” differentiation began within the first days of tumor residence with an initial phase in which T cells arrest, largely on tumor-associated macrophages. Within 10 days, cellular motility increased and resembled a random walk, suggesting a relative absence of TCR signaling. We then studied the concurrent and apparently contradictory phenomenon that many of these cells express molecular markers of activation and were visualized undergoing active cell division. We found that whereas proliferation did not require ongoing TCR/ZAP70 signaling, instead this is driven in part by intratumoral IL-15 cytokine. Thus, TILs undergo sequential reprogramming by the tumor microenvironment and are actively retained, even while being antigen insensitive. We conclude that this program effectively fills the niche with ineffective yet cytokine-dependent TILs, and we propose that these might compete with new clones, when they arise.

Authors

Bijan Boldajipour, Amanda Nelson, Matthew F. Krummel

×

Figure 4

Tumor-resident T cells proliferate in the tumor microenvironment.

Options: View larger image (or click on image) Download as PowerPoint
Tumor-resident T cells proliferate in the tumor microenvironment.
(A and...
(A and B) Expression of KI67 (A) and incorporation of EdU during DNA synthesis within 24 hours (B) in endogenous CD44hi CD8+ T cells (black), or high-affinity T cells (red), after arrival of OT-I T cells to the tumor (left) and after establishing residence (right). (C) Statistical analysis of EdU incorporation in several experiments. Mann-Whitney test, P > 0.05. (D and E) Snapshots of time-lapse videos of dividing high-affinity T cells (D, green) and endogenous T cells (E, red) in tumors of PyMT-ChOVA/CD2-RFP hosts. (E) CD11c+ antigen-presenting cells (APC, yellow) are visualized by the expression of an additional CD11c-YFP transgene, and blood vessels are labeled by Evans Blue (magenta). Arrows show dividing T cells and their daughter cells. Scale bar: 20 μm.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts